Retrospective study examining the impact of imeglimine on patients with type 2 diabetes mellitus complicated by MASLD.

Retrospective Study on the Effect of Imeglimin in Patients with Type 2 Diabetes Mellitus Complicated by Metabolic Dysfunction-Associated Steatotic Liver Disease - IME-MASLD: Imeglimin's Effect in Type 2 Diabetes Patients with MASLD - A Retrospective Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000058230

Enrollment

Registered

2025-06-20

Start date

2024-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

metabolic dysfunction associated steatotic liver disease type 2 diabetes

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with type 2 diabetes mellitus complicated by fatty liver/MASLD who attended an eligible medical institution during the period under study, with and without imeglimine use. 2) Patients for whom the required data collection items (see below) are recorded in the electronic medical record.

Exclusion criteria

Exclusion criteria: 1) Patients for whom the required data items cannot be collected in the medical record

Design outcomes

Primary

Measure	Time frame
Changes in HbA1c with and without imeglimine use in type 2 diabetes patients with MASLD.	—

Secondary

Measure	Time frame
Glucose tolerance related (GA, blood glucose, urinary albumin-creatinine ratio, blood C-peptide), fatty liver MASLD related (BMI, AST, ALT, G-GTP, ALP, T-Bil, ALB, PT, Total Cholesterol, TG, HDL Cholesterol, LDL Cholesterol, BUN, Cr, eGFR, Plt, Fib4 index, type 4 collagen 7S, autotaxin, M2BPGi, APRI, VCTE from fibroscan, CAP, FAST Score values, AGE, various InBody Changes in laboratory values (body weight, muscle mass, body fat percentage, extracellular water ratio)	—

Measure

Time frame

Glucose tolerance related (GA, blood glucose, urinary albumin-creatinine ratio, blood C-peptide), fatty liver MASLD related (BMI, AST, ALT, G-GTP, ALP, T-Bil, ALB, PT, Total Cholesterol, TG, HDL Cholesterol, LDL Cholesterol, BUN, Cr, eGFR, Plt, Fib4 index, type 4 collagen 7S, autotaxin, M2BPGi, APRI, VCTE from fibroscan, CAP, FAST Score values, AGE, various InBody Changes in laboratory values (body weight, muscle mass, body fat percentage, extracellular water ratio)

—

Countries

Japan

Contacts

Public Contactkensaku fukunaga

Kagawa university Department of Endocrinology and Metabolism

fukunaga.kensaku@kagawa-u.ac.jp0878912230

Outcome results